ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

HARVONI
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

HARVONI Rx

Generic Name and Formulations:
Ledipasvir, sofosbuvir; 90mg/400mg; tabs.

Company:
Gilead Sciences, Inc.

Therapeutic Use:

Indications for HARVONI:

Chronic hepatitis C virus (HCV) infection in patients with: genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis; genotype 1 with decompensated cirrhosis, in combination with ribavirin; or genotype 1 or 4 who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin.

Adult:

Test for HBV infection prior to initiation. 1 tab once daily. Genotype 1: Treatment-naïve without cirrhosis or with compensated cirrhosis (Child-Pugh A), or treatment-experienced without cirrhosis: treat for 12 weeks; treatment-naïve without cirrhosis who have pre-treatment HCV RNA <6 million IU/mL: can be considered for 8 weeks. Treatment-experienced with compensated cirrhosis: treat for 24 weeks; can be considered for 12 weeks with concomitant ribavirin (if eligible). Treatment-naïve and -experienced with decompensated cirrhosis (Child-Pugh B or C): treat for 12 weeks with ribavirin (see full labeling). Genotype 1 or 4: Treatment-naïve and -experienced liver transplant recipients without cirrhosis or with compensated cirrhosis: treat for 12 weeks with ribavirin. Genotype 4, 5, 6: Treatment-naïve and -experienced without cirrhosis or with compensated cirrhosis: treat for 12 weeks. HCV/HIV-1 co-infection: follow same dosage schedule. See full labeling.

Children:

<12yrs and <35kg: not established. Test for HBV infection prior to initiation. ≥12yrs or ≥35kg: 1 tab once daily. Genotype 1: Treatment-naïve without cirrhosis or with compensated cirrhosis (Child-Pugh A), or treatment-experienced without cirrhosis: treat for 12 weeks. Treatment-experienced with compensated cirrhosis: treat for 24 weeks. Genotype 4, 5, 6: Treatment-naïve and -experienced without cirrhosis or with compensated cirrhosis: treat for 12 weeks. HCV/HIV-1 co-infection: follow same dosage schedule. See full labeling.

Contraindications:

When co-administered with ribavirin, its contraindication also apply to this combination regimen (eg, Pregnancy Cat.X).

Warnings/Precautions:

Risk of HBV reactivation in patients coinfected with HCV/HBV. Test all patients for HBV infection by measuring HBsAg and anti-HBc; if positive serologic evidence, monitor for hepatitis flare or HBV reactivation during and at post-treatment follow-up; treat if clinically indicated. Increased risk of symptomatic bradycardia when concomitant amiodarone esp. patients also taking beta blockers or with cardiac comorbidities and/or advanced liver disease. Severe renal impairment (eGFR <30mL/min/1.73m2) or ESRD requiring hemodialysis. Decompensated cirrhosis. Pregnancy. Nursing mothers.

Interactions:

Concomitant certain immunosuppressants or chemotherapeutic agents: may increase risk of HBV reactivation. Concomitant amiodarone: not recommended; if no alternatives, monitor cardiac function (see full labeling). May increase absorption of concomitant P-gp and BCRP substrates. Concomitant P-gp inducers (eg, rifampin, St. John’s wort), other sofosbuvir-containing products, anticonvulsants (eg, carbamazepine, phenytoin, phenobarbital, oxcarbazepine), rifabutin, rifapentine, elvitegravir, cobicistat, emtricitabine, tenofovir DF, tipranavir/ritonavir, simeprevir, or rosuvastatin: not recommended. Separate dosing of antacids by 4hrs. May give H2-antagonists simultaneously or 12hrs apart (comparable to max famotidine 40mg twice daily). May give PPI doses (comparable to omeprazole ≤20mg) simultaneously under fasted conditions. May potentiate digoxin; monitor. Concomitant tenofovir DF regimens without a HIV protease inhibitor/ritonavir or cobicistat; monitor. Concomitant atazanavir/ritonavir or cobicistat + emtricitabine/tenofovir DF, darunavir/ritonavir or cobicistat + emtricitabine/tenofovir DF, or lopinavir/ritonavir + emtricitabine/tenofovir DF: consider alternatives; or if coadmin necessary, monitor.

Pharmacological Class:

HCV NS5A inhibitor + HCV NS5B polymerase inhibitor.

Adverse Reactions:

Fatigue, headache, asthenia, nausea, diarrhea, insomnia.

Note:

For ribavirin specific dosing and safety information, refer to the full prescribing information.

Generic Availability:

NO

How Supplied:

Tabs—28

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs